» Articles » PMID: 31032368

Improvement of K562 Cell Line Transduction by FBS Mediated Attachment to the Cell Culture Plate

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2019 Apr 30
PMID 31032368
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Lentiviral vectors have been used for gene therapy in the clinical phase in recent years. These vectors provide a tool for gene insertion, deletion, or modification in organisms. The K562 human cell line has been used extensively in hematopoietic research. Despite its broad application, it is hard-to-transfection and transduction. So, this study presents a simple method to increase the transduction efficiency of K562 cells with a low multiplicity of infection (MOI) of the virus particle. For this purpose, 24-well plate was coated by 300 l fetal bovine serum (FBS) before seeding. Then 2×10 K562 cells were seeded in each FBS coated plate. After 24h, K562 cells were attached and doubled. Different amount of lentivirus-based GFP vector according to MOI (5, 10, 15, and 20) along with 8 g polybrene was added to the attached K562 cells and after 6h cells and viral particle complex were spinfected. Then cells were returned to the plate and incubated in 37°C overnight. After 48h transduction efficiency was established by measuring the GFP-expressing cells by flow cytometry. Flow cytometry analysis showed that, after plate treatment by FBS, 64.5% transduction rate in K562 cells was achieved at MOI=20. Therefore, this method can be an effective and simple way to increase the lentiviral transduction rate for suspended cells such as K562.

Citing Articles

Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.

Lee C, Hsu K, Hsieh Y, Li W, Long Y, Lin C Cells. 2024; 13(7.

PMID: 38607055 PMC: 11011921. DOI: 10.3390/cells13070616.


The effect of microvesicles derived from K562 cells on proliferation and apoptosis of human bone marrow mesenchymal stem cells.

Rassaei N, Abbaszade Dibavar M, Soleimani M, Atashi A, Mohammadi M, Farsani M Iran J Basic Med Sci. 2023; 26(3):295-300.

PMID: 36865039 PMC: 9922373. DOI: 10.22038/IJBMS.2023.66903.14675.


The dark side of foetal bovine serum in extracellular vesicle studies.

Urzi O, Olofsson Bagge R, Crescitelli R J Extracell Vesicles. 2022; 11(10):e12271.

PMID: 36214482 PMC: 9549727. DOI: 10.1002/jev2.12271.


A Gene Transfer-Positive Cell Sorting System Utilizing Membrane-Anchoring Affinity Tag.

Yang L, Cui L, Ma S, Zuo Q, Huang Q Front Bioeng Biotechnol. 2022; 10:930966.

PMID: 35782508 PMC: 9244562. DOI: 10.3389/fbioe.2022.930966.


In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.

Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin M, Moya F Nat Commun. 2020; 11(1):5060.

PMID: 33033246 PMC: 7544871. DOI: 10.1038/s41467-020-18875-x.


References
1.
Naumann S, Reutzel D, Speicher M, Decker H . Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization. Leuk Res. 2001; 25(4):313-22. DOI: 10.1016/s0145-2126(00)00125-9. View

2.
Rainaldi G, Filippini P, Ferrante A, Indovina P, Santini M . Fibronectin facilitates adhesion of K562 leukemic cells normally growing in suspension to cationic surfaces. J Biomed Mater Res. 2001; 55(1):104-13. DOI: 10.1002/1097-4636(200104)55:1<104::aid-jbm140>3.0.co;2-0. View

3.
Logan A, Lutzko C, Kohn D . Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol. 2002; 13(5):429-36. DOI: 10.1016/s0958-1669(02)00346-4. View

4.
Konopka K . Enhancement of retroviral transduction by cationic liposomes. Methods Enzymol. 2004; 373:493-506. DOI: 10.1016/S0076-6879(03)73031-6. View

5.
Schakowski F, Buttgereit P, Mazur M, Marten A, Schottker B, Gorschluter M . Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther. 2004; 2(1):1. PMC: 331421. DOI: 10.1186/1479-0556-2-1. View